Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIM1 | P11309 | 13/20 | 0.41 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.39 |
| ▸ | ACHE | P22303 | 1/20 | 0.39 |
| ▸ | DYRK1A | Q13627 | 3/20 | 0.37 |
| ▸ | CLK1 | P49759 | 2/20 | 0.37 |
| ▸ | PIM3 | Q86V86 | 3/20 | 0.37 |
| ▸ | PIM2 | Q9P1W9 | 3/20 | 0.37 |
| ▸ | ULK1 | O75385 | 3/20 | 0.36 |
| ▸ | CLK2 | P49760 | 1/20 | 0.35 |
| ▸ | CLK3 | P49761 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3723072 | 0.90 | PIM1 (0.39) | PIM1CHEK1ACHEDYRK1ACLK1 | |
| SCHEMBL11908124 | 0.89 | PIM1 (0.40) | PIM1CHEK1ACHEDYRK1ACLK1 | |
| SCHEMBL11908678 | 0.89 | PIM1 (0.52) | PIM1CHEK1ACHEDYRK1ACLK1 | |
| SCHEMBL3723196 | 0.86 | PIM1 (0.43) | PIM1CHEK1ACHEDYRK1ACLK1 | |
| SCHEMBL473735 | 0.85 | CHEK1 (0.39) | PIM1CHEK1ACHEDYRK1ACLK1 | |
| SCHEMBL473778 | 0.84 | PIM1 (0.43) | PIM1CHEK1ACHEDYRK1ACLK1 | |
| SCHEMBL473795 | 0.84 | CHEK1 (0.40) | PIM1CHEK1ACHEDYRK1ACLK1 | |
| SCHEMBL473733 | 0.84 | CHEK1 (0.45) | PIM1CHEK1ACHEDYRK1APIM3 | |
| SCHEMBL11909922 | 0.84 | PIM1 (0.44) | PIM1CHEK1ACHEDYRK1ACLK1 | |
| SCHEMBL11908243 | 0.84 | BRAF (0.48) | PIM1CHEK1ACHEDYRK1APIM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120208809-A1 | 9H-PYRROLO[2,3-B: 5,4-C'] DIPYRIDINE AZACARBOLINE DERIVATIVES, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF | SANOFI (FR) | 2012-08-16 | — | — | US | claimed |
| WO-2010109084-A2 | 9H-PYRROLO[2,3-B: 5,4-C'] DIPYRIDINE AZACARBOLINE DERIVATIVES, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2010-09-30 | — | — | WO | claimed |
| US-20120208809-A1 | 9H-PYRROLO[2,3-B: 5,4-C'] DIPYRIDINE AZACARBOLINE DERIVATIVES, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF | SANOFI (FR) | 2012-08-16 | — | — | US | disclosed |
| US-20120208809-A1 | 9H-PYRROLO[2,3-B: 5,4-C'] DIPYRIDINE AZACARBOLINE DERIVATIVES, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF | SANOFI (FR) | 2012-08-16 | — | — | US | disclosed |
| EP-2411389-A2 | 9H-PYRROLO[2,3-B: 5,4-C']DIPYRIDINE AZACARBOLINE DERIVATIVES, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF | SANOFI (FR) | 2012-02-01 | — | — | EP | disclosed |
| WO-2010109084-A2 | 9H-PYRROLO[2,3-B: 5,4-C'] DIPYRIDINE AZACARBOLINE DERIVATIVES, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2010-09-30 | — | — | WO | disclosed |
| WO-2010109084-A2 | 9H-PYRROLO[2,3-B: 5,4-C'] DIPYRIDINE AZACARBOLINE DERIVATIVES, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2010-09-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120208809-A1 | 9H-PYRROLO[2,3-B: 5,4-C'] DIPYRIDINE AZACARBOLINE DERIVATIVES, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF | NPR3, CCNH, CBR3 | PIM1 3366/4885CHEK1 1152/4885ACHE 4455/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.